PharmAust and WEHI to Investigate Monepantel in HTLV-1 Viral...

PharmAust and WEHI to Investigate Monepantel in HTLV-1 Viral Infections

• 10-20 million HTLV-1 sufferers. Virus associated with pulmonary disease, inflammatory disorders and leukaemia/lymphoma
• Adds to PharmAust’s COVID-19 virus work by broadening the scope of potential monepantel antiviral activity
• Expected to provide preclinical models of high relevance to support clinical trials
• 12 July 2021 – Perth, Australia: PharmAust Limited (ASXAA), a clinical-stage biotechnology company, has executed a Research Services Agreement with the Walter and Eliza Hall Institute (WEHI), Melbourne to investigate the effects of monepantel (MPL) upon human T-lymphotrophic virus-1 (HTLV-1) infections in vitro.
• . The virus can cause a type of cancer called adult T-cell leukaemia/lymphoma (ATL) and is transmitted primarily through infected bodily fluids including blood and breast milk.
• Approximately 10-20 million people worldwide are infected with HTLV-1 with high recorded incidence in Japan1. Several central Australian indigenous populations have infection rates of over 60%. Infection is associated with pulmonary disease, inflammatory disorders and, in some cases, a rapidly progressive leukaemia/lymphoma. In 10% of patients serious morbidities and mortality is observed.
• This work follows upon PharmAust’s COVID-19 program, aiming to broaden the scope of targets for MPL’s potential antiviral activity. The study of HTLV-1 is of particular significance due to the readily available nature of highly and particularly relevant in vitro and in vivo preclinical virus infection models, potentially providing PharmAust with further data to support future human trials.
• Like the COVID-19 work, the HTLV-1 work will be conducted at WEHI by a group led by Professor Marc Pellegrini. Work will commence upon cell lines in culture. Dependent upon outcomes and subsequent agreement, the group aims to then move to in vivo preclinical models. The fee payable under the agreement is not material to the company. Preliminary data are anticipated in December 2021.
• PharmAust’s Chief Scientific Officer Dr Richard Mollard stated, “PharmAust is pleased to have the opportunity to work again with Professor Marc Pellegrini’s group at the WEHI. While PharmAust continues MPL manufacture and tablet production for clinical trials, this work provides an excellent opportunity to build our MPL antiviral knowledge base.
• While our COVID-19 work is ongoing, having a more extensive preclinical data package describing MPL’s antiviral activity in more general terms would strengthen PharmAust’s position going into any antiviral clinical trial, including for COVID-19.”

This announcement is authorised by the Board.
1 areas-high-prevalence-HTLV1.pdf
Enquiries:
Dr Roger Aston
Executive Chairman and CEO Tel: 0402 762 204 [email protected]
Dr Richard Mollard Chief Scientific Officer Tel: 0418 367 855
[email protected]


———

This ticks all there boxes and puts our primary product in the category of having a core formula that is more than possibly, a booster that some are now seeking for add to and redefine original.startup packages. Maybe possible.

Why a company in this position can’t have a higher SP when it appears of higher value. A large corporate would do the trick.

No volume of course, no one should sell at these prices. But of course desperate people do desperate things. Those who are not weary and look at shares in the cool of night look at things differently then.

We live in hope of glory when the facts absorb.